Daniela Pugliese
Overview
Explore the profile of Daniela Pugliese including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
121
Citations
1066
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Privitera G, Monastero L, Melita E, Schiavoni E, Napolitano D, Barini A, et al.
Dig Liver Dis
. 2025 Mar;
PMID: 40023750
Background: Data on nonmedical switching from one anti-Tumor Necrosis Factor (TNF)-α biosimilar to another in inflammatory bowel disease (IBD) are relatively sparse. We aimed to study the effects of nonmedical...
2.
Calvez V, Puca P, Di Vincenzo F, Del Gaudio A, Bartocci B, Murgiano M, et al.
Biomedicines
. 2025 Feb;
13(2).
PMID: 40002718
Inflammatory bowel diseases (IBDs), encompassing Crohn's disease and ulcerative colitis, are complex chronic disorders characterized by an intricate interplay between genetic predisposition, immune dysregulation, gut microbiota alterations, and environmental exposures....
3.
Lopetuso L, Deleu S, Puca P, Abreu M, Armuzzi A, Barbara G, et al.
Inflamm Bowel Dis
. 2025 Feb;
PMID: 39932857
Background: Fecal microbiota transplantation (FMT) is emerging as a potential treatment modality for individuals living with inflammatory bowel disease (IBD). Despite its promise, the effectiveness of FMT for treating IBD,...
4.
Mocci G, Tursi A, Scaldaferri F, Napolitano D, Pugliese D, Capobianco I, et al.
J Clin Med
. 2024 Dec;
13(23).
PMID: 39685651
Ustekinumab (UST) is an interleukin-12/interleukin-23 receptor antagonist approved for the treatment of Crohn's disease (CD). Only limited real-life data on the long-term outcomes of CD patients treated with UST are...
5.
Minordi L, Sacchetti F, Balzano D, Maresca R, DAngelo F, Larosa L, et al.
J Clin Med
. 2024 Nov;
13(22).
PMID: 39597812
This study investigated the radiological, clinical, and surgical factors linked to the risk of endoscopic recurrence following ileocolic resection for Crohn's disease. We conducted a retrospective analysis of data from...
6.
Goren I, Fallek Boldes O, Boldes T, Knyazev O, Kagramanova A, Limdi J, et al.
J Crohns Colitis
. 2024 Oct;
PMID: 39435855
Objectives: Elderly hospitalized patients with inflammatory bowel disease (IBD) flare and concurrent Clostridioides difficile infection (CDI) are considered at high risk of IBD-related complications. We aimed to evaluate the short,...
7.
Pessarelli T, Topa M, Sorge A, Nandi N, Pugliese D, Macaluso F, et al.
Nutrients
. 2024 Oct;
16(19).
PMID: 39408277
Background/objectives: Limited data exist on the epidemiology and clinical management of short bowel syndrome (SBS) and chronic intestinal failure (CIF) in Crohn's disease (CD). This study aimed to evaluate these...
8.
Potenza A, Nachira D, Sacchetti F, Trivisonno A, Pugliese D, Boskoski I, et al.
Therap Adv Gastroenterol
. 2024 Sep;
17:17562848241263014.
PMID: 39239070
Complex fistulizing perianal disease is a disabling manifestation of inflammatory bowel disease (IBD), seriously compromising patients 'quality of life'. The success rate of available treatments is quite low, and nearly...
9.
Minordi L, DAngelo F, Privitera G, Papa A, Larosa L, Laterza L, et al.
J Clin Med
. 2024 Jul;
13(14).
PMID: 39064186
Crohn's disease (CD) is a chronic, progressive inflammatory condition, involving primarily the bowel, characterized by a typical remitting-relapsing pattern. Despite endoscopy representing the reference standard for the diagnosis and assessment...
10.
Laterza L, Piscaglia A, Bibbo S, Arena V, Brisigotti M, Fabbretti G, et al.
J Pers Med
. 2024 May;
14(5).
PMID: 38793087
Mucosal healing (MH) is the main target in ulcerative colitis (UC) treatment. Even if MH lowers the risk of disease reactivation, some patients still relapse. Histologic activity (HA) beyond MH...